Multiple Myeloma

Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma

Obesity Increases Risk for Transformation of MGUS to Multiple Myeloma

By

Researchers sought to determine the influence of obesity on the transformation of MGUS, an asymptomatic plasma cell neoplasm, to multiple myeloma.

Racial Disparities Persist in Myeloma Treatment Use

Racial Disparities Persist in Myeloma Treatment Use

By

Investigators found black patients with multiple myeloma are less likely to use newer, more advanced treatments such as autologous HSCT or bortezumib, and explored factors contributing to this as well as the impact on this population.

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

Adding Bortezomib to Rd Improves PFS, OS in Newly Diagnosed Myeloma

By

Researchers investigated whether VRd, which has demonstrated significant efficacy in newly diagnosed multiple myeloma, would improve outcomes in patients with previously untreated myeloma who are not planned for immediate ASCT.

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

3-drug Regimen With Ricolinostat Active, Safe in Multiple Myeloma

By

Researchers report on an evaluation of the safety and preliminary efficacy of the HDAC6-selective inhibitor ricolinostat in combination with standard proteasome inhibitor therapy for relapsed or refractory multiple myeloma.

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

Longer Dosing Interval of Zoledronic Acid May Be Acceptable for Bone Metastases

By

Results from a phase 3 trial comparing a 12-week dosing interval with the standard 4-week dosing interval of zoledronic acid to reduce the incidence of skeletal-related events and pain in patients with bone metastases.

Selinexor Plus Low Dose Dex Active in Heavily Pretreated Refractory Myeloma

Selinexor Plus Low Dose Dex Active in Heavily Pretreated Refractory Myeloma

By

Selinexor in combination with low dose dexamethasone is active in heavily pretreated patients with refractory multiple myeloma.

BRd Safe, Efficacious as Second-line Treatment for R/R Myeloma

BRd Safe, Efficacious as Second-line Treatment for R/R Myeloma

By

The combination of bendamustine, lenalidomide, and dexamethasone was highly active as second-line treatment for relapsed/refractory multiple myeloma.

Elotuzumab Regimen Active in High-risk Smoldering Multiple Myeloma

Elotuzumab Regimen Active in High-risk Smoldering Multiple Myeloma

By

A study presented at 2016 ASH annual meeting demonstrated that the combination of elotuzumab, lenalidomide, and dexamethasone has potential in patients with high-risk smoldering multiple myeloma, a population that would otherwise not receive treatment.

Second Round of Treatment Does Not Improve PFS in Multiple Myeloma

Second Round of Treatment Does Not Improve PFS in Multiple Myeloma

By

A study presented at the 2016 Annual Meeting of ASH assessed the impact of additional interventions on progression-free survival in patients with multiple myeloma.

Beta-blockers May Improve Survival in Multiple Myeloma

Beta-blockers May Improve Survival in Multiple Myeloma

By

Administration of beta blockers in patients with newly diagnosed multiple myeloma may be associated with a reduced risk of cancer-specific death.

Thalidomide, Lenalidomide Equivalent With Respect to Survival in Myeloma

Thalidomide, Lenalidomide Equivalent With Respect to Survival in Myeloma

By

Thalidomide and lenalidomide are equivalent with respect to survival outcomes in patients with multiple myeloma.

FDA Approves Daratumumab Regimens for Relapsed Multiple Myeloma

FDA Approves Daratumumab Regimens for Relapsed Multiple Myeloma

By

The US FDA has granted approval for additional indications for daratumumab for the treatment of patients with multiple myeloma who have received prior therapies.

Overall Risk of Second Primary Malignancies is Low in Multiple Myeloma

Overall Risk of Second Primary Malignancies is Low in Multiple Myeloma

By

A panel of International Myeloma Working Group members  presents their review of current data on the potential host-, disease-, and treatment-related risk factors associated with the development of second primary malignancies in patients with multiple myeloma.

Vorinostat + Len-Dex Active in Lenalidomide-refractory Patients With Multiple Myeloma

Vorinostat + Len-Dex Active in Lenalidomide-refractory Patients With Multiple Myeloma

By

In this single-center, open-label, phase 2b trial, researchers determined if adding vorinostat to lenadolimide and dexamethasome would improve outcomes for patients with multiple myeloma refractory to lenalidomide.

Panobinostat, Bortezomib, Thalidomide Efficacious in Relapsed Myeloma

By

In this study, researchers sought to improve the safety of panobinostat plus bortezomib and dexamethasone for relapsed or relapsed and refractory multiple myeloma.

Daratumumab To Be Evaluated With Carfilzomib in Multiple Myeloma

Daratumumab To Be Evaluated With Carfilzomib in Multiple Myeloma

By

Amgen talks about its collaboration with Janssen Biotech Inc on clinical trials that assess the combination of carfilzomib (Kyprolis) with daratumumab (Darzalex) in patients with multiple myeloma.

Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma

Treatment Facility Volume Associated With Mortality Risk in Multiple Myeloma

By

Results of this data analysis demonstrate the relationship between treatment facility volume and all-cause mortality among patients with multiple myeloma.

Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma

Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma

By

The phase 3 PANORAMA 1 trial previously demonstrated that panobinostat plus bortezomib and dexamethasone significantly prolonged progression-free survival vs bortezomib and dexamethasone alone. Final overall survival analysis is presented.

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

Daratumumab With Len-Dex Prolongs PFS in R/R Multiple Myeloma

By

Adding daratumumab to lenalidomide and dexamethasone significantly prolonged progression-free survival compared with lenalidomide plus dexamethasone alone in patients with relapsed or refractory multiple myeloma.

Ixazomib + Dexamethasone Active in Relapsed Multiple Myeloma

Ixazomib + Dexamethasone Active in Relapsed Multiple Myeloma

By

The combination of ixazomib and dexamethasone is clinically active and well tolerated in patients with relapsed multiple myeloma not refractory to bortezomib.

Longer Maintenance Therapy Duration May Improve Survival in Myeloma

Longer Maintenance Therapy Duration May Improve Survival in Myeloma

By

A longer duration of lenalidomide maintenance therapy after autologous HSCT may improve progression-free and overall survival in patients with multiple myeloma.

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

Ciprofloxacin May Prevent Bacteremia in Patients Undergoing Auto-HSCT

By

Antibacterial prophylaxis with the flouroquinolone, ciprofloxacin, substantially reduced the risk of bacteremia and neutropenic fever in patients with multiple myeloma or lymphoma undergoing high-dose chemotherapy and auto-HSCT.

MRD Negativity Associated With Prolonged Survival in Myeloma

MRD Negativity Associated With Prolonged Survival in Myeloma

By

Minimal residual disease (MRD) negativity after treatment is associated with prolonged overall survival in patients with newly diagnosed multiple myeloma.

Study Assesses Infection Risk With Myeloma Therapies

Study Assesses Infection Risk With Myeloma Therapies

By

Researchers have determined the risk of infection for immunomodulatory drug-based therapy and proteasome inhibitor-based therapy with respect to treatment phase in patients with multiple myeloma.

Daratumumab Combo Improves PFS in Relapsed/Refractory Myeloma

Daratumumab Combo Improves PFS in Relapsed/Refractory Myeloma

By

Daratumumab plus bortezomib and dexamethasone improves progression-free survival in multiple myeloma.

Daratumumab Plus Len-Dex an Encouraging Combo for Multiple Myeloma

Daratumumab Plus Len-Dex an Encouraging Combo for Multiple Myeloma

By

Daratumumab plus lenalidomide and dexamethasone resulted in rapid, deep, durable responses in patients with multiple myeloma.

SES Factors Impact Survival of Younger Patients With Myeloma

SES Factors Impact Survival of Younger Patients With Myeloma

By

Sociodemographic factors, not race or ethnicity, impact survival of younger patients with multiple myeloma.

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

Addition of Elotuzumab to Bortezomib/Dexamethasone Improves Survival in Relapsed/Refractory Multiple Myeloma

By

The addition of elotuzumab to bortezomib/dexamethasone appears to increase progression-free survival in relapsed/refractory multiple myeloma (RRMM).

Family History Not Associated With Disease Progression in MGUS

Family History Not Associated With Disease Progression in MGUS

By

A family history of lymphoproliferative disorders is not a risk factor for progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma.

Adding Daratumumab to Lenalidomide/Dexamethasone Improves Survival in Multiple Myeloma

Adding Daratumumab to Lenalidomide/Dexamethasone Improves Survival in Multiple Myeloma

By

Treatment with daratumumab, lenalidomide, and dexamethasone (DRd) may be superior to lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs